Table 2.
Mutation | Study regimen | Trial identifier |
---|---|---|
IDH1mut or IDH2mut | AML | |
IDH1 mut | Ivosidenib or placebo + azacitidine | NCT03173248 |
IDH1 mut | Ivosidenib and CPX-351 | NCT04493164 |
IDH1 mut | Olutasidenib with azacitidine or cytarabine | NCT02719574 |
IDH2 mut | Enasidenib and venetoclax | NCT04092179 |
IDH1mut or IDH2mut | Ivosidenib or enasidenib with 7 + 3 followed by cytarabine or mitoxantrone/etoposide consolidation | NCT02632708 |